Role of D1/D2 dopamin receptors antagonist perphenazine in morphine analgesia and tolerance in rats

Bosnian Journal of Basic Medical Sciences

Volumn 13, Issue 2, 2013, Pages 119-125

  Ozdemir, Ercan ^a   Bagcivan, Ihsan ^a   Gursoy, Sinan ^a  

^a CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Analgesia; Dopamine receptors; Morphine tolerance; Perphenazine

Indexed keywords

EID: 84883747832     PISSN: 15128601     EISSN: 18404812     Source Type: Journal    
DOI: 10.17305/bjbms.2013.2394     Document Type: Article

References (49)

1. Mendez IA, Trujillo KA. NMDA receptor antagonists inhibit opi ate antinociceptive tolerance and locomotor sensitization in rats. Psychopharmacology 2008; 196:497-509.
2. Fischer BA, Ward SJ, Henry FE, Dykstra LA. Attenuation of morphine antinociceptive tolerance by a CBi receptor agonist and an NMDA receptor antagonist: Interactive effects. Neuropharmacology 2010; 58:544-550.
3. +/calmodulin-dependent protein kinase II. J Pharmacol Exp Ther 2006; 317:901-909.
4. Chen Y, Geis C, Sommer C. Activation of TRPVi contributes to morphine tolerance: Involvement of the mitogen-activated protein kinase signaling pathway. The J Neurosci 2008; 28:5836-5845.
5. Ozdemir E, Bagcivan I, Gursoy S, Altun A, Durmus N. effects of fl uoxetine and LY 365265 on tolerance to the analgesic eff ect of morphine in rats. Acta Physiol Hung 2011; 98:205-213.
6. Ozdemir E, Gursoy S, Bagcivan I. The effects of serotonin/nor-epinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats. J Physiol Sci 2012; 62:317-323.
7. Gursoy S, Ozdemir E, Bagcvan I, Altun A, Durmus N. effects of alpha 2-adrenoceptor agonists dexmedetomidine and guanfacine on morphine analgesia and tolerance in rats. Ups J Med Sci 2011; 116:238-246.
8. Llorens-Cortes C, Pollard H, Schwartz JC. Localization of opiate receptors in substantia nigra: evidence by lesion studies. Neurosci Lett 1979; 12:165-170.
9. Wu Z-Q, Chen J, Chi Z-Q, Liu J-G. Involvement of dopamine system in regulation of Na+,K+-ATPase in the striatum upon activation of opioid receptors by morphine. Mol Pharmacol 2007; 71:519-530.
10. Wise RA. Neurobiology of addiction. Curr Opin Neurobiol. 1996; 6(2):243-251.
11. Lu L, Su WJ, Yue W, Ge X, Su F, Pei G. et al. Attenuation of mor phine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. Life Sci. 2001; 69(1):37-46.
12. Wood PL. Opioid regulation of CNS dopaminergic pathways: a review of methodology, receptor types, regional variations and species differences. Peptides. 1983; 4(5):595-601.
13. Johnson DW, Glick SD. Dopamine release and metabolism in nucleus accumbens and striatum of morphine tolerant and nontoler-ant rats. Pharmacol Biochem Behav 1993; 46:341-347.
14. Goodman RR, Aider BA, Pasternak GW. Regional distribution of opioid receptors. In: Pasternak GW (ed.), The opiate receptors, Hu-mana Press, New York 1988; 197-228.
15. Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 1993; 16:299-321.
16. Vallone D, Picetti R, Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev 2000; 24:125-132.
17. Sealfon SC, Olanow CW. Dopamine receptors: from structure to behavior. Trends Neurosci 2000; 23: 34-40.
18. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature 1979;277:93-96.
19. Le Moine C, Bloch B. Di and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of Di and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol. 1995;355(3):4l8-426.
20. Pothos E, Rada P, Mark GP, Hoebel BG. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 1991; 566:348-350.
21. Bontempi B, Sharp FR. Systemic morphine-induced c-Fos protein in the rat striatum and nucleus accumbens is regulated by mu opioid receptors in the substantia nigra and ventral tegmental area. J Neurosci 1997; 17:8596-8612.
22. Zarrindast MR, Moghaddampour E. Opposing infl uences of D-i and D-2 dopamine receptors activation on morphine-induced an-tinociception. Arch Int Pharmacodyn Ther. 1989;300:37-50.
23. Barasi S, Duggal KN. Teeff ect of local and systemic application of dopaminergic agents on tail fl ick latency in the rat. Eur J Pharmacol 1985; 117:287-294.
24. Marder SR. Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA, eds. Psychiatry. Philadelphia: W.B. Saunders 2008; 1569-1585.
25. Zarrindast MR, Dinkoub Z, Homayoun H, Bakhtiarian A, Kha-vandgar S. Dopamine receptor mechanism(s) and morphine tolerance in mice. J Psychopharmacol. 2002;16(3):261-266.
26. Kanaan SA, Saadé NE, Haddad JJ, Abdelnoor AM, Atweh SF, Jab-bur SJ, Safieh-Garabedian B. Endotoxin-induced local infl ammation and hyperalgesia in rats and mice: a new model for inflammatory pain. Pain. 1996;66(2-3):373-379.
27. Ramabadran K, Bansinath M, Turndorf H, Puig MM. Tehyper-algesic eff ect of naloxone is attenuated in streptozotocin-diabetic mice. Psychopharmacology (Berl.) 1989; 97:169-174.
28. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008;8:78-97.
29. Unterwald EM, Cuntapay M. Dopamine-opioid interactions in the rat striatum: a modulatory role for dopamine Di receptors in delta opioid receptor-mediated signal transduction. Neuropharmacol-ogy. 2000; 39(3):372-381.
30. 1 dopamine receptor antagonists. Neurosci Lett 1991; 125:201-204.
31. Voorn P, Docter GJ, Jongen-Relo AL, Jonker AJ. Rostrocaudal subregional diff erences in the response of enkephalin, dynorphin and substance P synthesis in rat nucleus accumbens to dopamine depletion. Eur J Neurosci 1994; 6:486-496.
32. Terashvili M, Wu HE, Schwasinger ET, Hung KC, Hong JS, Tseng LF. (+)-Morphine attenuates the (-)-morphine-produced conditioned place preference and the mu-opioid receptor-mediated dopamine increase in the posterior nucleus accumbens of the rat. Eur J Pharmacol 2008; 587:147-154.
33. Alper RH, Demarest KT, Moore KE. Morphine diff erentially alters synthesis and turnover of dopamine in central neuronal systems. J Bosn J Basic Med Sci 2013; 13 (2): 124-125
34. Devine DP, Leone P, Pocock D, Wise RA. Diff erential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo mícrodíalysís studies. J Pharmacol Exp Ther 1993; 266:1236-1246.
35. Yonehara N, Clouet DH. effects of delta and mu opiopeptides on the turnover and release of dopamine in rat stríatum. J Pharmacol Exp Ther 1984; 231: 38-42.
36. Johnson SW, North RA. Opioids excite dopamine neurons by hy-perpolarízatíon of local intemeurons. J Neurosci 1992; 12:483-488.
37. Chartoff EH, Mague SD, Barhight MF, Smith AM, Carlezon WA. Behavioral and molecular effects of dopamine Di receptor stimulation during naloxone-precipitated morphine withdrawal. J Neurosci 2006; 26:6450-6457.
38. Rezayof A, Amíní R, Rassoulí Y, Zarrindast MR. Infl uence of nitric oxide on morphine-induced amnesia and interactions with dopa-minergic receptor agents. Physiol Behav 2006; 88:124-131.
39. Zarrindast MR, Zarghi A. Morphine stimulates locomotor activity by an indirect dopaminergic mechanism: possible Di and D2 receptor involvement. Gen Pharmacol 1992; 23:1221-1225
40. Weiss J, Tompson ML, Shuster L. effects of naloxone and naltrex-one on drug-induced hypothermia in mice. Neuropharmacology. 1984;23(5):483-489.
41. Dizgah IM, Karimian SM, Zarrindast MR, Sohanakí H. Attenuation of morphine withdrawal signs by a Di-receptor agonist in the locus coeruleus of rats. NeuroReport 2005; 16:1683-1686.
42. Kuribara H. Modifi cation of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice. Eur J Pharmacol. 1995; 275(3):251-258.
43. Zarrindast M-R, Asgarí-Afshar A, Sahebgharaní M. Morphine-induced antinociception in the formalin test: sensitization and interactions with Di and D2 dopamine receptors and nitric oxide agents. Behav Pharmacol 2007; 18:177-184.
44. Wang ZJ, Wang LX. Phosphorylation: a molecular switch in opioid tolerance. Life Sci 2006; 79:1681-1691.
45. Wang ZJ, Tang L, Xin L. Reversal of morphine antinociceptive tolerance by acute spinal inhibition of Ca'Vcalmodulin-dependent protein kinase II. Eur J Pharmacol 2003; 465:199-200.
46. Yang C, Chen Y, Tang L, Wang ZJ. Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence. J Pharmacol Exp Ther. 2011;338(1):164-172.
47. Wu Z-Q, Li M, Chen J, Chi Z-Q, Liu J-G. Involvement of cAMP/ cAMP-dependent protein kinase signaling pathway in regulation of Na*,K*-ATPase upon activation of opioid receptors by morphine. Mol Pharmacol. 2006;69:866-876.
48. Yamaguchi I, Walk SF, Jose PA, Felder RA. Dopamine D2L receptors stimulate Na*/K(*)-ATPase activity in murine LTK-cells. Mol Pharmacol. 1996; 49(2):373-378.
49. Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A. et al. DARPP-32: regulator of the efficacy of dopaminergic neu-rotransmission. Science. 1998;281(5378):838-842.